SCHEMBL581245

SCHEMBL581245

COC(=O)N1CCC(C(=O)O)CC1Cc1cc(C(C)(C)C)cc(C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 9/20 0.38
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CETP P11597 2/20 0.34
OPRK1 P41145 1/20 0.34
CYP2D6 P10635 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL587434 0.96 OPRK1 (0.39) TACR1NPC1RAB9ACETPOPRK1
SCHEMBL587545 0.91 OPRK1 (0.42) TACR1NPC1RAB9ACETPOPRK1
SCHEMBL581238 0.89 NPC1 (0.41) TACR1NPC1RAB9ACYP2D6CYP3A4
SCHEMBL3081551 0.88 TACR1 (0.39) TACR1CETPALDH1A1HPGDNPSR1
SCHEMBL3087575 0.84 MEN1 (0.36) TACR1NPC1RAB9ACETPALDH1A1
SCHEMBL581268 0.84 MEN1 (0.36) TACR1NPC1RAB9ACETPALDH1A1
SCHEMBL581269 0.84 MEN1 (0.36) TACR1NPC1RAB9ACETPALDH1A1
SCHEMBL581312 0.84 TACR1 (0.43) TACR1CETPCYP2D6CYP3A4CYP2C19
SCHEMBL581731 0.84 PSEN1 (0.36) TACR1NPC1RAB9AOPRK1CYP2D6
SCHEMBL581620 0.83 TACR1 (0.35) TACR1NPC1RAB9AOPRK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459246-B Isoxazol-3 (2H) -one analogs as therapeutic agents ASTRAZENECA AB 2014-05-07 CN disclosed
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
CN-102459246-A Isoxazol-3 (2H) -one analogs as therapeutic agents ASTRAZENECA AB 2012-05-16 CN disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 TACR1 474/4885NPC1 497/4885RAB9A 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.